CA2341810A1 - Peptides cycliques derives de la prosaposine et leurs utilisations - Google Patents

Peptides cycliques derives de la prosaposine et leurs utilisations Download PDF

Info

Publication number
CA2341810A1
CA2341810A1 CA002341810A CA2341810A CA2341810A1 CA 2341810 A1 CA2341810 A1 CA 2341810A1 CA 002341810 A CA002341810 A CA 002341810A CA 2341810 A CA2341810 A CA 2341810A CA 2341810 A1 CA2341810 A1 CA 2341810A1
Authority
CA
Canada
Prior art keywords
amino acid
peptide
acid
hydrophobic amino
hydrophobic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341810A
Other languages
English (en)
Inventor
David E. Wright
John S. O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341810A1 publication Critical patent/CA2341810A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des peptides cycliques neurotrophiques et analgésiques issus de la région active de la prosaposine et présentant une séquence consensus X¿1?X¿2?X¿3?NNX¿4?TX¿5?X¿6?X¿7?X¿8? (SEQ. ID NO. 4) dans laquelle X¿1? est un acide aminé hydrophobe (leucine, isoleucine, valine, tyrosine, tryptophan, phénylalanine ou méthionine); X¿2? est un acide aminé hydrophobe; X¿3? est un acide aspartique, un acide glutamique, lysine or arginine; N est asparagine, X¿4? est un quelconque acide aminé; T est thréonine, X¿5? est un acide glutamique ou un acide aspartique; X¿6? est un quelconque acide aminé, X¿7? est un acide aminé hydrophobe; et X¿8? est un acide aminé hydrophobe. Ces peptides sont utiles pour l'activation de l'excroissance neuronale, la prévention de la mort cellulaire, l'activation de la myélinisation, le traitement de troubles neurodégénératifs et le traitement et la prévention de douleurs neurophatiques.
CA002341810A 1998-08-28 1999-08-20 Peptides cycliques derives de la prosaposine et leurs utilisations Abandoned CA2341810A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9835998P 1998-08-28 1998-08-28
US60/098,359 1998-08-28
PCT/US1999/019378 WO2000012553A1 (fr) 1998-08-28 1999-08-20 Peptides cycliques derives de la prosaposine et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2341810A1 true CA2341810A1 (fr) 2000-03-09

Family

ID=22268937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341810A Abandoned CA2341810A1 (fr) 1998-08-28 1999-08-20 Peptides cycliques derives de la prosaposine et leurs utilisations

Country Status (13)

Country Link
EP (1) EP1105420A1 (fr)
JP (2) JP4528443B2 (fr)
KR (1) KR20010079695A (fr)
CN (1) CN1324367A (fr)
AU (1) AU751034B2 (fr)
BR (1) BR9913490A (fr)
CA (1) CA2341810A1 (fr)
CZ (1) CZ2001655A3 (fr)
HU (1) HUP0103265A3 (fr)
IL (1) IL141586A0 (fr)
PL (1) PL204359B1 (fr)
WO (1) WO2000012553A1 (fr)
ZA (1) ZA200102489B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
CZ2001655A3 (cs) * 1998-08-28 2001-11-14 Myelos Corporation Cyklický peptid, prostředek, způsob indukce myelinizace, způsob potlačení degenerace neuronů a způsob léčby
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
BRPI0710945A2 (pt) 2006-04-28 2012-03-13 Children's Hospital Medical Center Propriedades fusogênicas de saposina c e proteínas e peptídeos relacionados para aplicação a sistemas de distribuição de fármaco transmembrana
JP5253402B2 (ja) * 2006-10-20 2013-07-31 チルドレンズ ホスピタル メディカル センター 自発的に形成する楕円体の単層リン脂質小胞
CN103275187B (zh) * 2013-06-14 2014-10-29 四川合泰新光生物科技有限公司 一种镇痛肽fi及其基因和应用
ES2877403T3 (es) 2015-04-23 2021-11-16 Procter & Gamble Suministro de agente anticaspa soluble en tensioactivo
CA3014923C (fr) 2016-03-03 2021-10-19 Sean Michael Renock Composition antipelliculaire en aerosol
WO2018075836A1 (fr) 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de mousse de shampooing concentré fournissant des bienfaits en matière de soins capillaires
EP3528896A1 (fr) 2016-10-21 2019-08-28 The Procter & Gamble Company Dosage de shampooing concentré de mousse pour fournir des bénéfices de soins capillaires
EP3528899B1 (fr) 2016-10-21 2024-04-10 The Procter & Gamble Company Dosage de mousse destiné à distribuer un volume de dosage et une quantité de tensioactif souhaités par un consommateur dans un espace de formulation optimal
WO2018075847A1 (fr) 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de shampooing concentré de mousse désignant des avantages de volume des cheveux
CN109843383A (zh) 2016-10-21 2019-06-04 宝洁公司 用于在最佳制剂空间中递送消费者期望的剂量体积、表面活性剂量和头皮健康剂量的泡沫剂型
CN109789076A (zh) 2016-10-21 2019-05-21 宝洁公司 具有低粘度和粘度降低剂的稳定致密洗发剂产品
US11154467B2 (en) 2016-10-21 2021-10-26 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair conditioning benefits
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
CN111278416A (zh) 2017-10-10 2020-06-12 宝洁公司 含低无机盐的无硫酸盐个人清洁组合物
WO2019074991A1 (fr) 2017-10-10 2019-04-18 The Procter & Gamble Company Composition de shampooing compacte comprenant des tensioactifs anioniques à base d'acides aminés et des polymères cationiques
EP3694479A1 (fr) 2017-10-10 2020-08-19 The Procter and Gamble Company Méthode de traitement des cheveux ou de la peau avec une composition de soins personnels sous forme de mousse
WO2019074989A1 (fr) 2017-10-10 2019-04-18 The Procter & Gamble Company Composition de shampooing compacte contenant des tensioactifs exempts de sulfate
CN111556743B (zh) 2017-12-20 2023-07-18 宝洁公司 包含硅氧烷聚合物的澄清洗发剂组合物
US11318073B2 (en) 2018-06-29 2022-05-03 The Procter And Gamble Company Low surfactant aerosol antidandruff composition
JP7410298B2 (ja) 2019-12-06 2024-01-09 ザ プロクター アンド ギャンブル カンパニー 頭皮活性物質の付着を強化する硫酸塩を含まない組成物
MX2022009191A (es) 2020-02-27 2022-08-18 Procter & Gamble Composiciones anticaspa con azufre que tienen eficacia y estetica mejoradas.
MX2023005963A (es) 2020-12-04 2023-06-07 Procter & Gamble Composiciones para el cuidado del cabello que comprenden materiales de reduccion del mal olor.
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
CZ2001655A3 (cs) * 1998-08-28 2001-11-14 Myelos Corporation Cyklický peptid, prostředek, způsob indukce myelinizace, způsob potlačení degenerace neuronů a způsob léčby

Also Published As

Publication number Publication date
WO2000012553A1 (fr) 2000-03-09
HUP0103265A2 (hu) 2002-02-28
ZA200102489B (en) 2002-06-04
BR9913490A (pt) 2001-09-25
AU751034B2 (en) 2002-08-08
JP2002523518A (ja) 2002-07-30
PL346346A1 (en) 2002-02-11
IL141586A0 (en) 2002-03-10
JP4528443B2 (ja) 2010-08-18
KR20010079695A (ko) 2001-08-22
EP1105420A1 (fr) 2001-06-13
PL204359B1 (pl) 2010-01-29
HUP0103265A3 (en) 2002-09-30
AU5690599A (en) 2000-03-21
CN1324367A (zh) 2001-11-28
CZ2001655A3 (cs) 2001-11-14
JP2010150272A (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
AU751034B2 (en) Cyclic prosaposin-derived peptides and uses thereof
CA2168029C (fr) Peptides derives de la prosaposine et de la cytokine, agents therapeutiques
AU734566B2 (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides
US5571787A (en) Prosaposin as a neurotrophic factor
WO1989009225A1 (fr) Peptides du facteur de croissance des neurones du systeme nerveux peripherique
US20050164948A1 (en) Methods of treatment with prosaposin-derived peptides
US6458357B1 (en) Retro-inverso neurotrophic and analgesic peptides
WO1998039357A1 (fr) Procedes pour soulager les douleurs neuropathiques
WO1998042746A9 (fr) Peptides neurotrophiques de synthese derives de la saposine c
WO1998042746A2 (fr) Peptides neurotrophiques de synthese derives de la saposine c
WO2000077029A1 (fr) Peptides retro inverses derives du facteur d'inhbition de la leucemie
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof
AU2002300005B2 (en) Method of alleviating neuropathic pain
US20020128193A1 (en) Retro-inverso prosaposin-derived peptides and use thereof
AU4267297A (en) Method of alleviating neuropathic pain

Legal Events

Date Code Title Description
FZDE Discontinued